Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
557.97
-6.66 (-1.18%)
Oct 13, 2025, 4:00 PM EDT - Market closed
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
$940,964
Profits / Employee
$295,154
Market Cap
57.85B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | 8,100 | 700 | 9.46% |
Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
Dec 31, 2017 | 6,200 | 800 | 14.81% |
Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
Dec 31, 2014 | 2,925 | 585 | 25.00% |
Dec 31, 2013 | 2,340 | 390 | 20.00% |
Dec 31, 2012 | 1,950 | 246 | 14.44% |
Dec 31, 2011 | 1,704 | 309 | 22.15% |
Dec 31, 2010 | 1,395 | 366 | 35.57% |
Dec 31, 2009 | 1,029 | 110 | 11.97% |
Dec 31, 2008 | 919 | 237 | 34.75% |
Dec 31, 2007 | 682 | 109 | 19.02% |
Dec 31, 2006 | 573 | -15 | -2.55% |
Dec 31, 2005 | 588 | -142 | -19.45% |
Dec 31, 2004 | 730 | 86 | 13.35% |
Dec 31, 2003 | 644 | -25 | -3.74% |
Dec 31, 2002 | 669 | 94 | 16.35% |
Dec 31, 2001 | 575 | 84 | 17.11% |
Dec 31, 2000 | 491 | 54 | 12.36% |
Dec 31, 1999 | 437 | 66 | 17.79% |
Dec 31, 1998 | 371 | 101 | 37.41% |
Dec 31, 1997 | 270 | 27 | 11.11% |
Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
REGN News
- 1 day ago - DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss - GlobeNewsWire
- 3 days ago - What If You Were Missing The Value In Regeneron Pharmaceuticals Stock? - Forbes
- 4 days ago - US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer - Reuters
- 5 days ago - Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation - GlobeNewsWire
- 6 days ago - 11 Cheap Stocks for a Market That's Too Expensive - Barrons
- 7 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 12 days ago - Regeneron: Growth Catalysts Incoming - Seeking Alpha
- 12 days ago - Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 - GlobeNewsWire